The Next Generation of Weight-Loss Drugs Is Coming: How to Choose What's Right for You

The battle for the obesity treatment market is escalating: daily pills approved in the US, monthly and quarterly injections in trials, and combination drugs aiming to preserve muscle mass. A review of new treatments, trial results, and the challenges that remain.

The battle for the obesity treatment market is escalating, bringing a new generation of solutions. This article reviews the most advanced treatments in development or already approved for use. In the United States, two daily pills have recently been approved: a pill version of Wegovy (semaglutide) and Eli Lilly's Foundayo (orforglipron), approved via an accelerated pathway in April 2026. Meanwhile, Pfizer is developing a monthly injection called berobenatide, which showed up to 12.3% weight loss beyond placebo in a Phase 2 trial. Amgen is developing MariTide, a long-acting injection that showed an average weight loss of up to 20% in a Phase 2 trial, and is currently being tested in monthly, bimonthly, and quarterly dosing. The most intriguing drug is Eli Lilly's retatrutide, which activates three hormonal receptors (GLP-1, GIP, and glucagon) and showed an average weight loss of 28.3% over 80 weeks in a Phase 3 trial. Novo Nordisk is developing CagriSema, a weekly injection combining semaglutide with cagrilintide, which showed a 12.4% reduction in patients with type 2 diabetes. A key challenge is muscle loss during weight reduction; a combination therapy with apitegromab alongside tirzepatide is being tested to preserve muscle. The article emphasizes that most treatments are still experimental, positive results do not guarantee approval, and medical supervision and follow-up are required.